

September 1, 2025

**BSE Limited**  
Floor 25, P. J. Towers  
Dalal Street,  
**Mumbai - 400 001**

**National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex, Bandra (E),  
**Mumbai - 400 051**

Scrip Code: **530019**

Symbol: **JUBLPHARMA**

Dear Sir / Madam

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")**

Pursuant to Regulation 30 of the SEBI Listing Regulations, and in continuation of our earlier communication dated June 12, 2025, we wish to inform you that the Company has successfully completed on September 1, 2025 the sale and transfer of its Active Pharmaceutical Ingredients (API) Business to Jubilant Biosys Limited ("JBL"), a wholly-owned subsidiary of the Company, in accordance with the terms of the Business Transfer Agreement ("BTA").

The details of the transaction were previously disclosed in our letter dated June 12, 2025, enclosed therein as **Annexure A**.

This intimation is also being made available on the Company's website and can be accessed on Company's website at [www.jubilantpharmova.com](http://www.jubilantpharmova.com)

We request you to kindly take the above on record and acknowledge receipt of this communication.

Date and time of event – September 1, 2025; 04:20 pm (IST).

Thanking you,

Yours faithfully,

For Jubilant Pharmova Limited

Naresh Kapoor  
Company Secretary and Compliance Officer

